Cargando…
Neural stem/progenitor cell therapy for Alzheimer disease in preclinical rodent models: a systematic review and meta-analysis
BACKGROUND: Alzheimer’s disease (AD) is a common progressive neurodegenerative disease characterized by memory impairments, and there is no effective therapy. Neural stem/progenitor cell (NSPC) has emerged as potential novel therapy for AD, and we aim to explore whether neural stem/progenitor cell t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814315/ https://www.ncbi.nlm.nih.gov/pubmed/36600321 http://dx.doi.org/10.1186/s13287-022-03231-1 |
_version_ | 1784864106393632768 |
---|---|
author | Zhou, Zijing Shi, Ben Xu, Yaxing Zhang, Jinyu liu, Xin Zhou, Xinghong Feng, Baofeng Ma, Jun Cui, Huixian |
author_facet | Zhou, Zijing Shi, Ben Xu, Yaxing Zhang, Jinyu liu, Xin Zhou, Xinghong Feng, Baofeng Ma, Jun Cui, Huixian |
author_sort | Zhou, Zijing |
collection | PubMed |
description | BACKGROUND: Alzheimer’s disease (AD) is a common progressive neurodegenerative disease characterized by memory impairments, and there is no effective therapy. Neural stem/progenitor cell (NSPC) has emerged as potential novel therapy for AD, and we aim to explore whether neural stem/progenitor cell therapy was effective for rodent models of AD. METHODS: We searched PubMed, Embase, Cochrane Library and Web of Science up to December 6, 2022. The outcomes included cognitive function, pathological features and BDNF. The GetData Graph Digitizer software (version 2.26) was applied to extract numerical values, and RevMan 5.3 and Stata 16 were used to analyze data. The SYRCLE risk of bias tool was used to assess study quality. RESULTS: We evaluated 22 mice studies and 8 rat studies. Compared to control groups, cognitive function of NSPC groups of both mice studies (SMD = − 1.96, 95% CI − 2.47 to − 1.45, I(2) = 75%, P < 0.00001) and rat studies (SMD = − 1.35, 95% CI − 2.11 to − 0.59, I(2) = 77%, P = 0.0005) was apparently improved. In mice studies, NSPC group has lower Aβ deposition (SMD = − 0.96, 95% CI − 1.40 to − 0.52, P < 0.0001) and p-tau level (SMD = − 4.94, 95% CI − 7.29 to − 2.95, P < 0.0001), higher synaptic density (SMD = 2.02, 95% CI 0.50–3.55, P = 0.009) and BDNF (SMD = 1.69, 95% CI 0.61–2.77, P = 0.002). Combined with nanoformulation (SMD = − 1.29, 95% CI − 2.26 to − 0.32, I(2) = 65%, P = 0.009) and genetically modified (SMD = − 1.29, 95% CI − 1.92 to − 0.66, I(2) = 60%, P < 0.0001) could improve the effect of NSPC. In addition, both xenogeneic and allogeneic transplant of NSPC could reverse the cognitive impairment of AD animal models. CONCLUSIONS: Our results suggested that NSPC therapy could improve the cognitive function and slow down the progression of AD. Due to the limitations of models, more animal trials and clinical trials are needed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-022-03231-1. |
format | Online Article Text |
id | pubmed-9814315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98143152023-01-06 Neural stem/progenitor cell therapy for Alzheimer disease in preclinical rodent models: a systematic review and meta-analysis Zhou, Zijing Shi, Ben Xu, Yaxing Zhang, Jinyu liu, Xin Zhou, Xinghong Feng, Baofeng Ma, Jun Cui, Huixian Stem Cell Res Ther Review BACKGROUND: Alzheimer’s disease (AD) is a common progressive neurodegenerative disease characterized by memory impairments, and there is no effective therapy. Neural stem/progenitor cell (NSPC) has emerged as potential novel therapy for AD, and we aim to explore whether neural stem/progenitor cell therapy was effective for rodent models of AD. METHODS: We searched PubMed, Embase, Cochrane Library and Web of Science up to December 6, 2022. The outcomes included cognitive function, pathological features and BDNF. The GetData Graph Digitizer software (version 2.26) was applied to extract numerical values, and RevMan 5.3 and Stata 16 were used to analyze data. The SYRCLE risk of bias tool was used to assess study quality. RESULTS: We evaluated 22 mice studies and 8 rat studies. Compared to control groups, cognitive function of NSPC groups of both mice studies (SMD = − 1.96, 95% CI − 2.47 to − 1.45, I(2) = 75%, P < 0.00001) and rat studies (SMD = − 1.35, 95% CI − 2.11 to − 0.59, I(2) = 77%, P = 0.0005) was apparently improved. In mice studies, NSPC group has lower Aβ deposition (SMD = − 0.96, 95% CI − 1.40 to − 0.52, P < 0.0001) and p-tau level (SMD = − 4.94, 95% CI − 7.29 to − 2.95, P < 0.0001), higher synaptic density (SMD = 2.02, 95% CI 0.50–3.55, P = 0.009) and BDNF (SMD = 1.69, 95% CI 0.61–2.77, P = 0.002). Combined with nanoformulation (SMD = − 1.29, 95% CI − 2.26 to − 0.32, I(2) = 65%, P = 0.009) and genetically modified (SMD = − 1.29, 95% CI − 1.92 to − 0.66, I(2) = 60%, P < 0.0001) could improve the effect of NSPC. In addition, both xenogeneic and allogeneic transplant of NSPC could reverse the cognitive impairment of AD animal models. CONCLUSIONS: Our results suggested that NSPC therapy could improve the cognitive function and slow down the progression of AD. Due to the limitations of models, more animal trials and clinical trials are needed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-022-03231-1. BioMed Central 2023-01-05 /pmc/articles/PMC9814315/ /pubmed/36600321 http://dx.doi.org/10.1186/s13287-022-03231-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Zhou, Zijing Shi, Ben Xu, Yaxing Zhang, Jinyu liu, Xin Zhou, Xinghong Feng, Baofeng Ma, Jun Cui, Huixian Neural stem/progenitor cell therapy for Alzheimer disease in preclinical rodent models: a systematic review and meta-analysis |
title | Neural stem/progenitor cell therapy for Alzheimer disease in preclinical rodent models: a systematic review and meta-analysis |
title_full | Neural stem/progenitor cell therapy for Alzheimer disease in preclinical rodent models: a systematic review and meta-analysis |
title_fullStr | Neural stem/progenitor cell therapy for Alzheimer disease in preclinical rodent models: a systematic review and meta-analysis |
title_full_unstemmed | Neural stem/progenitor cell therapy for Alzheimer disease in preclinical rodent models: a systematic review and meta-analysis |
title_short | Neural stem/progenitor cell therapy for Alzheimer disease in preclinical rodent models: a systematic review and meta-analysis |
title_sort | neural stem/progenitor cell therapy for alzheimer disease in preclinical rodent models: a systematic review and meta-analysis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814315/ https://www.ncbi.nlm.nih.gov/pubmed/36600321 http://dx.doi.org/10.1186/s13287-022-03231-1 |
work_keys_str_mv | AT zhouzijing neuralstemprogenitorcelltherapyforalzheimerdiseaseinpreclinicalrodentmodelsasystematicreviewandmetaanalysis AT shiben neuralstemprogenitorcelltherapyforalzheimerdiseaseinpreclinicalrodentmodelsasystematicreviewandmetaanalysis AT xuyaxing neuralstemprogenitorcelltherapyforalzheimerdiseaseinpreclinicalrodentmodelsasystematicreviewandmetaanalysis AT zhangjinyu neuralstemprogenitorcelltherapyforalzheimerdiseaseinpreclinicalrodentmodelsasystematicreviewandmetaanalysis AT liuxin neuralstemprogenitorcelltherapyforalzheimerdiseaseinpreclinicalrodentmodelsasystematicreviewandmetaanalysis AT zhouxinghong neuralstemprogenitorcelltherapyforalzheimerdiseaseinpreclinicalrodentmodelsasystematicreviewandmetaanalysis AT fengbaofeng neuralstemprogenitorcelltherapyforalzheimerdiseaseinpreclinicalrodentmodelsasystematicreviewandmetaanalysis AT majun neuralstemprogenitorcelltherapyforalzheimerdiseaseinpreclinicalrodentmodelsasystematicreviewandmetaanalysis AT cuihuixian neuralstemprogenitorcelltherapyforalzheimerdiseaseinpreclinicalrodentmodelsasystematicreviewandmetaanalysis |